S-1/A: Onconetix Files Amendment No. 1 to Form S-1 for Potential $25 Million Equity Line of Credit

Onconetix, Inc. has filed an amendment to its Form S-1 registration statement to register the potential sale of up to 50,000,000 shares of common stock through an equity line of credit with Keystone Capital Partners, LLC, aiming to raise up to $25 million.

Summary

• Onconetix, Inc., a commercial stage biotechnology company, filed Amendment No. 1 to its Form S-1 registration statement on February 7, 2025.
• The filing relates to the offer and sale of up to 50,000,000 shares of common stock by Keystone Capital Partners, LLC, the selling stockholder.
• These shares may be issued to Keystone under a Common Stock ELOC Purchase Agreement, establishing an equity line of credit.
• Onconetix may receive up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement.
• The actual proceeds may be less depending on the number of shares sold and the price at which they are sold.
• The company will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus.
• The purchase price per share will fluctuate based on the market price of Onconetix's shares at the time of sale.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol ONCO.
• The last reported sale price on February 5, 2025, was $0.6644 per share.
• The company is registering the shares on behalf of the Selling Stockholder, to be offered and sold by it from time to time.
• The company has paid all of the registration expenses incurred in connection with the registration of the shares.
• The company will not pay any of the selling commissions, brokerage fees and related expenses.

Sentiment

Score: 4

Explanation: The announcement is neutral to slightly negative. While it secures potential funding, it also highlights the company's need for capital and the potential for dilution. The uncertainty around accessing the full ELOC amount and the fluctuating purchase price contribute to the lower sentiment score.

Positives

• The ELOC provides a potential source of funding for Onconetix, with up to $25.0 million available.
• The company has already raised approximately $2.9 million through the ELOC as of January 15, 2025.
• The company believes that its current cash balance is sufficient to fund its operations through the end of February 2025.

Negatives

• The company will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus.
• The actual proceeds from Keystone may be less than $25.0 million depending on the number of shares sold and the price at which they are sold.
• The purchase price per share will fluctuate based on the market price of Onconetix's shares at the time of sale, which could lead to dilution.
• The company's ability to access the full amount available under the ELOC is uncertain.
• The company believes that its current cash balance is sufficient to fund its operations through the end of February 2025.

Risks

• The company's ability to access the full $25.0 million under the ELOC is not guaranteed.
• The market price of Onconetix's common stock could decline, impacting the proceeds received from the ELOC.
• Sales of common stock under the ELOC could cause dilution to existing shareholders.
• The company's reliance on third parties for the commercialization of Proclarix poses a risk.
• The company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may be unable to timely pay amounts due to Veru, from whom it purchased ENTADFI in April 2023.
• The company is dependent on third parties, including Labcorp, to develop, market, distribute and sell its products.

Future Outlook

The company expects to continue to incur net losses in the foreseeable future and will need to raise additional capital to fund its operations.

Industry Context

This announcement reflects a common financing strategy for biotechnology companies, particularly those in the development stage, to secure capital for research, development, and commercialization activities. The use of an ELOC provides flexibility in accessing funds based on market conditions.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector often utilize equity lines of credit or similar financing mechanisms to fund operations, especially during the clinical trial and commercialization phases.
• The terms of the ELOC, including the potential dilution and the fluctuating purchase price, are typical for this type of financing arrangement.
• Other companies that have used similar financing strategies include [hypothetical company A] and [hypothetical company B], although the specific terms and conditions may vary based on the company's financial situation and market conditions.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares under the ELOC.
• The company's ability to fund its operations and commercialize its products will be impacted by the success of the ELOC.
• Employees' job security and future prospects are tied to the company's financial stability.

Next Steps

• Onconetix will continue to commercialize Proclarix.
• The company will explore strategic alternatives to monetize ENTADFI.
• The company will seek additional funding through equity or debt financings.

Key Dates

Keywords

ELOC, equity line of credit, common stock, Keystone Capital Partners, Onconetix, financing, prospectus, shares, proceeds, sale